无载体纳米药物向葡萄糖代谢,用于增强类风湿性关节炎治疗
Tao Chen1, Xin Lin2, Daming Li2
1Institute of Biomedical Engineering, College of Medicine, Southwest Jiaotong University, Chengdu 610031, China; Key Laboratory of Advanced Technologies of Materials, Ministry of Education and School of Materials Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China.
Colloids and surfaces. B, Biointerfaces
|November 29, 2023
概括
这项研究引入了一种新的无载体纳米药物,它结合了2-脱氧-D-葡萄糖 (2-DG) 和黄素 (Cur) 来治疗类风湿性关节炎 (RA). 这种2-DG/Cur纳米药物 (2-DCNP) 有效地向炎症关节,抑制糖解并减少关节炎症小鼠的炎症.
科学领域:
- 生物医学工程 生物医学工程
- 纳米医学是一种纳米医学.
- 类风湿病学 类风湿病学
背景情况:
- 类风湿性关节炎 (RA) 的特点是炎症关节的葡萄糖分解显著增加,以满足能源需求.
- 目前的治疗方法面临着挑战,因为药物清除速度快,分布不特定.
- 纳米载体提供有针对性的输送,但可以引起毒性,并且具有较差的药物载荷.
研究的目的:
- 开发一种无载体纳米药物,用于针对性类风湿性关节炎治疗.
- 为了研究一个自组装的2-脱氧-D-葡萄糖和黄素纳米药物 (2-DCNP) 的疗效.
- 探索针对炎症性RA关节中高血糖分解的潜力.
主要方法:
- 2-脱氧-D-葡萄糖 (2-DG) 和黄素 (Cur) 自组合成无载体纳米药物 (2-DCNP).
- 利用2-DG对葡萄糖载体蛋白1 (GLUT1) 的高亲和力,在炎症细胞上进行向输送.
- 在关节炎的老鼠模型中评估2-DCNP的治疗疗效.
主要成果:
- 自组装的2-DCNP有效地抑制了炎症关节中的糖解.
- 2-DCNP在治疗关节炎大鼠方面表现出显著的治疗疗效.
- 2-DCNP的无载体性质可以避免与载体材料相关的潜在副作用.
结论:
- 无载体2-DCNP通过向和调节葡萄糖代谢,为风湿性关节炎治疗提供了一个有希望的策略.
- 这种方法避免了与载体相关的毒性,并改善了药物的生物可用性.
- 针对炎症关节中的糖解,为RA缓解提供了一个新的治疗途径.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
209
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
209
01:24Glucagon-like Receptor Agonists
329
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
329